503 related articles for article (PubMed ID: 12854090)
21. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants.
Revaz V; Zurbriggen R; Moser C; Schiller JT; Ponci F; Bobst M; Nardelli-Haefliger D
Antiviral Res; 2007 Oct; 76(1):75-85. PubMed ID: 17617476
[TBL] [Abstract][Full Text] [Related]
22. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
23. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
24. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.
Villa LL; Ault KA; Giuliano AR; Costa RL; Petta CA; Andrade RP; Brown DR; Ferenczy A; Harper DM; Koutsky LA; Kurman RJ; Lehtinen M; Malm C; Olsson SE; Ronnett BM; Skjeldestad FE; Steinwall M; Stoler MH; Wheeler CM; Taddeo FJ; Yu J; Lupinacci L; Railkar R; Marchese R; Esser MT; Bryan J; Jansen KU; Sings HL; Tamms GM; Saah AJ; Barr E
Vaccine; 2006 Jul; 24(27-28):5571-83. PubMed ID: 16753240
[TBL] [Abstract][Full Text] [Related]
25. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
Stanley M; Lowy DR; Frazer I
Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
[TBL] [Abstract][Full Text] [Related]
26. Preventative and therapeutic vaccines for cervical cancer.
Roden R; Wu TC
Expert Rev Vaccines; 2003 Aug; 2(4):495-516. PubMed ID: 14711335
[TBL] [Abstract][Full Text] [Related]
27. [Cervical cancer prevention: the impact of HPV vaccination].
Monsonégo J
Gynecol Obstet Fertil; 2006 Mar; 34(3):189-201. PubMed ID: 16529969
[TBL] [Abstract][Full Text] [Related]
28. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.
Da Silva DM; Pastrana DV; Schiller JT; Kast WM
Virology; 2001 Nov; 290(2):350-60. PubMed ID: 11883199
[TBL] [Abstract][Full Text] [Related]
29. Human papillomavirus vaccines.
Stanley MA
Rev Med Virol; 2006; 16(3):139-49. PubMed ID: 16710836
[TBL] [Abstract][Full Text] [Related]
30. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination.
Stern PL
J Clin Virol; 2005 Mar; 32 Suppl 1():S72-81. PubMed ID: 15753015
[TBL] [Abstract][Full Text] [Related]
31. Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells.
Mossadegh N; Gissmann L; Müller M; Zentgraf H; Alonso A; Tomakidi P
Virology; 2004 Aug; 326(1):57-66. PubMed ID: 15262495
[TBL] [Abstract][Full Text] [Related]
32. The human papillomavirus vaccines.
Ljubojević S
Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
[TBL] [Abstract][Full Text] [Related]
33. NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16.
Pastrana DV; Vass WC; Lowy DR; Schiller JT
Virology; 2001 Jan; 279(1):361-9. PubMed ID: 11145917
[TBL] [Abstract][Full Text] [Related]
34. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine.
Emeny RT; Wheeler CM; Jansen KU; Hunt WC; Fu TM; Smith JF; MacMullen S; Esser MT; Paliard X
J Virol; 2002 Aug; 76(15):7832-42. PubMed ID: 12097595
[TBL] [Abstract][Full Text] [Related]
35. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
[TBL] [Abstract][Full Text] [Related]
36. Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells.
Lenz P; Lowy DR; Schiller JT
Eur J Immunol; 2005 May; 35(5):1548-56. PubMed ID: 15832296
[TBL] [Abstract][Full Text] [Related]
37. Human papillomavirus vaccines.
Stanley MA
Curr Opin Mol Ther; 2002 Feb; 4(1):15-22. PubMed ID: 11883690
[TBL] [Abstract][Full Text] [Related]
38. Japanese encephalitis protein vaccine candidates expressing neutralizing epitope and M.T hsp70 induce virus-specific memory B cells and long-lasting antibodies in swine.
Fei-fei G; Jian W; Feng X; Li-ping S; Quan-yun S; Jin-ping Z; Pu-yan C; Pei-hong L
Vaccine; 2008 Oct; 26(44):5590-4. PubMed ID: 18761388
[TBL] [Abstract][Full Text] [Related]
39. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.
Roden RB; Yutzy WH; Fallon R; Inglis S; Lowy DR; Schiller JT
Virology; 2000 May; 270(2):254-7. PubMed ID: 10792983
[TBL] [Abstract][Full Text] [Related]
40. [Immunogenicity study of HPV 6b virus-like particles].
Liu Y; Liu X; Frazer IH
Zhonghua Yi Xue Za Zhi; 2002 May; 82(9):587-9. PubMed ID: 12133476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]